Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Cancer Res. 2014 Oct 21;74(24):7260–7273. doi: 10.1158/0008-5472.CAN-14-0876

Figure 6. RAG1 animals treated with an NK cell depleting antibody have increased viral infection and have a survival advantage with Myxoma therapy.

Figure 6

Wildtype (n=5 for each treatment) or RAG1-deficient (n=5 for each treatment) animals with 14 day K1492 tumours were treated with intraperitoneal injections of 200 μg anti-NK1.1 antibody or isotype control at -2 and 0 days post-infection with 5×106 PFU of vMyx-FLuc. Animals were monitored for bioluminescence (A, C, D) and survival via the Kaplan-Meier method (B, D, F).